Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.

Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, Madan RA, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs PM, Lindenberg L, Dahut W, Choyke PL.

AJR Am J Roentgenol. 2019 Oct 15:1-9. doi: 10.2214/AJR.19.21264. [Epub ahead of print]

PMID:
31613660
2.

A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience.

Baiocco JA, Ball MW, Pappajohn AK, Rayn KN, Bratslavsky G, Boyle SL, Linehan WM, Metwalli AR.

Urol Oncol. 2019 Jun;37(6):356.e1-356.e7. doi: 10.1016/j.urolonc.2019.02.015. Epub 2019 Mar 20.

PMID:
30902489
3.

CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors.

Vocke CD, Ricketts CJ, Ball MW, Schmidt LS, Metwalli AR, Middelton LA, Killian JK, Khan J, Meltzer PS, Simonds WF, Merino MJ, Linehan WM.

Urology. 2019 Feb;124:91-97. doi: 10.1016/j.urology.2018.11.013. Epub 2018 Nov 16.

4.

Low-dose, short course alteplase treatment of submassive pulmonary embolism: a case series from the National Institutes of Health Clinical Center.

Lozier JN, Elinoff JM, Suffredini AF, Rosing DR, Sidenko S, Sherry RM, Metwalli AR, Sachdev V, Danner RL, Chang R.

Blood Coagul Fibrinolysis. 2018 Dec;29(8):701-707. doi: 10.1097/MBC.0000000000000774.

PMID:
30300148
5.

Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy.

Salter CA, Cullen J, Kuo C, Chen Y, Hurwitz L, Metwalli AR, Dimitrakoff J, Rosner IL.

Biomed Res Int. 2018 Jun 28;2018:4727089. doi: 10.1155/2018/4727089. eCollection 2018.

6.

BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes.

Hasumi H, Furuya M, Tatsuno K, Yamamoto S, Baba M, Hasumi Y, Isono Y, Suzuki K, Jikuya R, Otake S, Muraoka K, Osaka K, Hayashi N, Makiyama K, Miyoshi Y, Kondo K, Nakaigawa N, Kawahara T, Izumi K, Teranishi J, Yumura Y, Uemura H, Nagashima Y, Metwalli AR, Schmidt LS, Aburatani H, Linehan WM, Yao M.

Hum Mol Genet. 2018 May 14. doi: 10.1093/hmg/ddy181. [Epub ahead of print]

7.

Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement.

Paschall AK, Mirmomen SM, Symons R, Pourmorteza A, Gautam R, Sahai A, Dwyer AJ, Merino MJ, Metwalli AR, Linehan WM, Malayeri AA.

Abdom Radiol (NY). 2018 Sep;43(9):2424-2430. doi: 10.1007/s00261-017-1453-4.

PMID:
29520425
8.

Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population.

Jha A, Ling A, Millo C, Gupta G, Viana B, Lin FI, Herscovitch P, Adams KT, Taïeb D, Metwalli AR, Linehan WM, Brofferio A, Stratakis CA, Kebebew E, Lodish M, Civelek AC, Pacak K.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):787-797. doi: 10.1007/s00259-017-3896-9. Epub 2017 Dec 4.

9.
10.

Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Yang Y, Vocke CD, Ricketts CJ, Wei D, Padilla-Nash HM, Lang M, Sourbier C, Killian JK, Boyle SL, Worrell R, Meltzer PS, Ried T, Merino MJ, Metwalli AR, Linehan WM.

Genes Chromosomes Cancer. 2017 Oct;56(10):719-729. doi: 10.1002/gcc.22476. Epub 2017 Jul 24.

11.

What is the Optimal Management Strategy for Multifocal and Hereditary Kidney Cancer?

Baiocco JA, Metwalli AR.

J Ren Med. 2017;1(1). pii: 5. Epub 2017 Apr 1. No abstract available.

12.

Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health.

An JY, Kim D, Tanakchi S, Semerjian AM, Thomas A, Boyle SL, Hassan R, Metwalli AR.

Clin Genitourin Cancer. 2017 Oct;15(5):e871-e875. doi: 10.1016/j.clgc.2017.04.022. Epub 2017 May 22. No abstract available.

13.

Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation.

McGowan A, An JY, Tanakchi S, Maruf M, Muthigi A, George A, Su D, Merino MJ, Linehan WM, Boyle SL, Metwalli AR.

Urol Case Rep. 2017 Apr 27;13:107-109. doi: 10.1016/j.eucr.2017.03.017. eCollection 2017 Jul.

14.

Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau.

DiBianco JM, An JY, Tanakchi S, Stanik Z, McGowan A, Maruf M, Sidana A, Jain AL, Muthigi A, George AK, Bayne C, Linehan WM, Boyle SL, Metwalli AR.

Urol Case Rep. 2017 Apr 27;13:101-103. doi: 10.1016/j.eucr.2017.02.015. eCollection 2017 Jul.

15.
16.

Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.

Hammerich KH, Donahue TF, Rosner IL, Cullen J, Kuo HC, Hurwitz L, Chen Y, Bernstein M, Coleman J, Danila DC, Metwalli AR.

Urol Oncol. 2017 Jul;35(7):460.e21-460.e28. doi: 10.1016/j.urolonc.2017.02.001. Epub 2017 Apr 11.

PMID:
28410987
17.

Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.

Vocke CD, Ricketts CJ, Merino MJ, Srinivasan R, Metwalli AR, Middelton LA, Peterson J, Yang Y, Linehan WM.

Genes Chromosomes Cancer. 2017 Jun;56(6):484-492. doi: 10.1002/gcc.22452. Epub 2017 Mar 31.

18.

H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.

Hasumi H, Hasumi Y, Baba M, Nishi H, Furuya M, Vocke CD, Lang M, Irie N, Esumi C, Merino MJ, Kawahara T, Isono Y, Makiyama K, Warner AC, Haines DC, Wei MH, Zbar B, Hagenau H, Feigenbaum L, Kondo K, Nakaigawa N, Yao M, Metwalli AR, Marston Linehan W, Schmidt LS.

Hum Mol Genet. 2017 Jan 15;26(2):354-366. doi: 10.1093/hmg/ddw392.

19.

Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print).

Watson MJ, Sidana A, Singer EA, Gupta GN, Rastinehad AR, Vourganti S, Bratslavsky G, Metwalli AR.

Int Urol Nephrol. 2017 Feb;49(2):267-268. doi: 10.1007/s11255-016-1433-6. Epub 2016 Oct 27. No abstract available.

PMID:
27812784
20.

Editorial Comment.

Metwalli AR.

J Urol. 2017 Jan;197(1):29. doi: 10.1016/j.juro.2016.07.106. Epub 2016 Oct 13. No abstract available.

PMID:
27746136
21.

Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes.

Watson MJ, Sidana A, Diaz AW, Siddiqui MM, Hankins RA, Bratslavsky G, Linehan WM, Metwalli AR.

J Endourol. 2016 Nov;30(11):1219-1226. Epub 2016 Oct 20.

22.

Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney.

Hankins RA, Walton-Diaz A, Truong H, Shih J, Bratslavsky G, Pinto PA, Marston Linehan W, Metwalli AR.

Int Urol Nephrol. 2016 Nov;48(11):1817-1821. Epub 2016 Aug 11.

23.

Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy.

Sidana A, Walton-Diaz A, Truong H, Siddiqui MM, Miao N, Shih J, Mannes A, Bratslavsky G, Linehan WM, Metwalli AR.

Int Urol Nephrol. 2016 Jul;48(7):1047-1053. doi: 10.1007/s11255-016-1284-1. Epub 2016 Apr 19.

24.

Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.

Li QQ, Hao JJ, Zhang Z, Hsu I, Liu Y, Tao Z, Lewi K, Metwalli AR, Agarwal PK.

Int J Oncol. 2016 Jun;48(6):2591-607. doi: 10.3892/ijo.2016.3478. Epub 2016 Apr 7.

25.

PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.

Turkbey B, Lindenberg ML, Adler S, Kurdziel KA, McKinney YL, Weaver J, Vocke CD, Anver M, Bratslavsky G, Eclarinal P, Kwarteng G, Lin FI, Yaqub-Ogun N, Merino MJ, Linehan WM, Choyke PL, Metwalli AR.

Abdom Radiol (NY). 2016 Jan;41(1):109-18. doi: 10.1007/s00261-015-0599-1.

PMID:
26830617
26.

Nephron-sparing surgery for multifocal and hereditary renal tumors.

Metwalli AR, Linehan WM.

Curr Opin Urol. 2014 Sep;24(5):466-73. doi: 10.1097/MOU.0000000000000094. Review.

27.

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, Lesperance J, Porter C, Sterbis J, McLeod DG.

Urol Oncol. 2014 Aug;32(6):761-8. doi: 10.1016/j.urolonc.2014.03.024. Epub 2014 Jun 11.

28.

The genetic basis of pheochromocytoma and paraganglioma: implications for management.

Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM.

Urology. 2014 Jun;83(6):1225-32. doi: 10.1016/j.urology.2014.01.007. Epub 2014 Mar 15. Review.

29.

Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.

Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.

J Clin Oncol. 2014 Feb 10;32(5):431-7. doi: 10.1200/JCO.2013.50.8192. Epub 2013 Dec 30.

30.

Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review.

Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2014 May;113(5b):E28-33. doi: 10.1111/bju.12344. Review.

31.

Commentary on: "Focal cryosurgical ablation of the prostate: a single institute's perspective".

Metwalli AR, Pinto PA.

BMC Urol. 2013 Aug 2;13:39. doi: 10.1186/1471-2490-13-39.

32.

Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.

Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middelton LA, Kauffman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM.

J Urol. 2013 Dec;190(6):1990-8. doi: 10.1016/j.juro.2013.06.012. Epub 2013 Jun 11.

33.

A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.

Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PLM, Eng C, Linehan WM, Brugarolas J.

Mol Cancer Res. 2013 Sep;11(9):1061-1071. doi: 10.1158/1541-7786.MCR-13-0111. Epub 2013 May 24.

34.

Diagnosis and management of BHD-associated kidney cancer.

Stamatakis L, Metwalli AR, Middelton LA, Marston Linehan W.

Fam Cancer. 2013 Sep;12(3):397-402. doi: 10.1007/s10689-013-9657-4. Review.

35.

Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database.

Vourganti S, Harbin A, Singer EA, Shuch B, Metwalli AR, Agarwal PK.

J Cancer. 2013 May 6;4(4):336-42. doi: 10.7150/jca.6215. Print 2013.

36.

Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome.

Volkin D, Yerram N, Ahmed F, Lankford D, Baccala A, Gupta GN, Hoang A, Nix J, Metwalli AR, Lang DM, Bratslavsky G, Linehan WM, Pinto PA.

J Pediatr Surg. 2012 Nov;47(11):2077-82. doi: 10.1016/j.jpedsurg.2012.07.003.

37.

Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.

Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.

J Urol. 2012 Dec;188(6):2063-71. doi: 10.1016/j.juro.2012.08.030. Epub 2012 Oct 18.

38.

Economic burden of repeat renal surgery on solitary kidney--do the ends justify the means? A cost analysis.

Agochukwu NQ, Metwalli AR, Kutikov A, Pinto PA, Linehan WM, Bratslavsky G.

J Urol. 2012 Nov;188(5):1695-700. doi: 10.1016/j.juro.2012.07.029. Epub 2012 Sep 19.

39.

Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.

Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM.

Cancer Biol Ther. 2010 Nov 1;10(9):885-92. doi: 10.4161/cbt.10.9.13237. Epub 2010 Nov 1.

40.

Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis.

Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ, Hazle JD, Dinney CP.

BJU Int. 2010 Dec;106(11):1799-804. doi: 10.1111/j.1464-410X.2010.09424.x.

41.

A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.

Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME, So AI.

BJU Int. 2007 Dec;100(6):1377-84. Epub 2007 Sep 10.

42.

Controversial issues and optimal management of stage T1G3 bladder cancer.

Metwalli AR, Kamat AM.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1283-94. Review.

PMID:
16925494
43.

Visual impairment after laparoscopic donor nephrectomy.

Metwalli AR, Davis RG, Donovan JF.

J Endourol. 2004 Nov;18(9):888-90. Review.

PMID:
15659927
44.

Congenital midureteral stricture in children diagnosed with antenatal hydronephrosis.

Smith BG, Metwalli AR, Leach J, Cheng EY, Kropp BP.

Urology. 2004 Nov;64(5):1014-9.

PMID:
15533497
45.

Tissue engineering in urology: where are we going?

Metwalli AR, Colvert JR 3rd, Kropp BP.

Curr Urol Rep. 2003 Apr;4(2):156-63. Review.

PMID:
12648435
46.

Inguinal hernia after laparoscopic orchiopexy.

Metwalli AR, Cheng EY.

J Urol. 2002 Nov;168(5):2163. No abstract available.

PMID:
12394749
47.

Supplemental Content

Loading ...
Support Center